Global Contrast Media/Contrast Agent Market to Around USD 5.6 Billion By 2030

The global contrast media/contrast agent market size was worth around USD 4.1 Billion in 2021 and is predicted to grow to around USD 5.6 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 3.5% between 2022 and 2030.

In medical imaging, a contrast medium or contrast agent is used to improve the contrast of internal body structures or fluids. As the picture contrast is enhanced, the anatomical organs and structures are imaged more clearly. As a result, it is highly useful in major surgeries as well as diagnostic procedures like CT scans. With a rise in surgical operations and imaging diagnosis, the market for contrast media, also known as contrast agents, is expanding quickly.

Although the contrast media market is currently in its development stage, it will grow over the next few years. The rise in image-guided surgical procedures, improvements in diagnostic technologies, an increase in diagnostic imaging, and an increase in the prevalence of cancer and heart problems are some of the factors contributing to the market's expansion. The market is expanding as a result of factors including the increased acceptance of contrast agents and the rise in the number of diagnostic centers that have enhanced diagnostic imaging services.

Advanced methods, such as the use of a gas microbubble in MRI imaging, are projected to accelerate market expansion. However, the side effects and allergies related to the contrast agent pose a major challenge to the market growth during the forecast period.

The global contrast media/contrast agent market is segmented based on modality, product type, application, mode of administration, end-use, and region.

Based on the modality, the global market is bifurcated into X-ray/CT, MRI, and Ultrasound. The X-ray/CT segment accounted for the largest market share in 2021 and is expected to show its dominance during the forecast period. High-resolution 3D pictures of structures are produced with the aid of X-ray/CT contrast agents. In X-ray and CT procedures, barium-based and iodinated contrast fluids are used. When supplied or injected into the body, barium, and iodine contrast agents block X-rays and prevent the rays from passing through. Images of the body's organs, blood vessels, and other tissues that momentarily contain barium- or iodinated-based contrast agents alter as a result.

The widespread use of X-rays and CT for a variety of disorders is anticipated to propel market expansion. On the other hand, the ultrasound segment is expected to grow at the fastest CAGR during the forecast period. To see tissue microcirculation, contrast agents for ultrasound imaging have been created. Microbubbles are typically used as the modality's agents because they improve the blood's echogenicity, allowing for better imaging and evaluation of tissue vascularity, major veins, and heart cavities. The significant advantages that ultrasound contrast agents have over other imaging modalities are expected to drive the market's expansion.

Based on the product type, the global contrast media/contrast agent market is categorized into iodinated, barium-based, gadolinium-based, and microbubble. The iodinated segment is projected to hold the largest market share over the forecast period. The segment growth is attributed to the availability of nonionic stable iodinated chemicals as well as the strong penetration of X-ray and CT techniques that allow for enhanced diagnosis. Although iodinated contrast agents are often injected intravenously, barium-based agents may rarely be used instead for rectal and oral delivery. CT and X-ray images are enhanced using contrast materials with an iodine base.

They are utilized to improve the vision of the brain, GI tract, internal organs, arteries, and veins. Iodinated contrasting media are frequently used for several reasons, including cancer, gastrointestinal, cardiovascular, musculoskeletal, neurological, and nephrological problems.

Based on the application, the global contrast media/contrast agent is divided into cardiovascular disorders, neurological disorders, gastrointestinal disorders, cancer, nephrological disorders, musculoskeletal disorders, and others. The neurological disorders segment is expected to dominate the market during the forecast period. The use of MRI contrast agents is encouraged by the diagnostic assessment of the CNS for neurological disorders because they offer superior images of neural structures than CT.

Gadolinium-based contrast agents are used to see demyelinated, inflammatory, and neoplastic lesions. One in three MRIs include gadolinium-based contrast agents to improve picture quality, which increases diagnostic precision by making blood arteries, inflammation, and tumors more visible.

The most frequently utilized macrocyclic gadolinium-based contrast agents in the United States for the diagnosis of neurological diseases are Gadavist, Dotarem, and Prohance. To identify lesions with aberrant vascularity in the brain, spine, and related tissues, they are authorized for intravenous use in adults and pediatric patients, 2 years of age or older.

Based on the route of administration, the global market is segmented into an intravascular route, oral route, rectal route, and others.

Based on the end-use, the market is segmented into hospitals, clinics, ambulatory surgery centers, and diagnostic imaging centers.

North America is expected to dominate the global contrast media/contrast agent market during the forecast period. The factors owing to which the market is growing include improved MRI procedures in cardiovascular diseases, policies of reimbursements for contrast media, strong infrastructure, and advanced cath-lab. Besides, the Asia Pacific region is also experiencing good market growth owing to the factors such as the advancement in technology and the rise in the rate of cardiac disorders.

This review is based on a report by Zion Market Research, titled “Contrast Media/Contrast Agent Market By Modality (X-ray/CT, MRI, and Ultrasound), By Product Type (Iodinated, Barium-based, Gadolinium-based, and Microbubble), By Application (Cardiovascular Disorders, Neurological Disorders, Gastrointestinal Disorders, Cancer, Nephrological Disorders, Musculoskeletal Disorders, and Others), By Route of Administration (Intravascular Route, Oral Route, Rectal Route, and Others), By End Use (Hospital, Clinics, Ambulatory Surgery Centers and Diagnostic Imaging Centers) and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2030.”- Report at https://www.zionmarketresearch.com/report/contrast-media-contrast-agent-market

Recent Development:

• In July 2022, Fresenius Kabi announced the availability of a portfolio of generic contrast media agents in the United States, beginning with the sale of Iodixanol Injection, USP, a medicine listed as in low supply by the U.S. Food and Drug Administration (FDA). Iodixanol Injection, USP is the first generic iso-osmolar, dimeric iodinated contrast media agent approved by the FDA for use in diagnostic x-ray imaging such as computed tomography (CT) scans.

The global contrast media/contrast agent market is dominated by players like:

• Bracco Imaging Spa
• CMC Contrast AB
• GE Healthcare
• Guerbet Group
• Nanopet Pharma GmbH.
• Sanochemia Pharmazeutika AG
• Subhra Pharma Private Ltd.
• Covidien
• Daiichi Sankyo Co. Ltd.
• Genovis AB
• Lantheus Medical Imaging Inc.
• Nanoscan Imaging LLC.
• Spago Imaging AB
• Taejoon Pharm Co. Ltd.

The global contrast media/contrast agent market is segmented as follows:

By Modality

• X-ray/CT
• MRI
• Ultrasound

By Product Type

• Iodinated
• Barium-based
• Gadolinium-based
• Microbubble

By Application

• Cardiovascular Disorders
• Neurological Disorders
• Gastrointestinal Disorders
• Cancer
• Nephrological Disorders
• Musculoskeletal Disorders
• Others

By Route of Administration

• Intravascular Route
• Oral Route
• Rectal Route
• Others

By End Use

• Hospital
• Clinics
• Ambulatory Surgery Centers
• Diagnostic Imaging Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com